BioNTech Analyst Price Targets - Benzinga

BioNTech SE

BNTXNASDAQ

Trade with Public

Trade with Public

$87.53

-0.64-0.73%

Últ. Act.: Nov 2, 4:00 PM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

© 2026 Benzinga | All Rights Reserved

BioNTech Analyst Price Targets - Benzinga

BioNTech Analyst Price Targets

Wall Street analyst price targets and consensus rating for BioNTech (BNTX).

Price Target Range — 12 Quarters

Analyst Consensus — 17 Analysts

13Buy

4Hold

Consensus RatingBuy# Analysts17Avg. Consensus PT$131Upside to Avg. PT+49.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 14, 2026	Canaccord Genuity	John Newman	PT Cut	Buy	$136→$132
Oct 7, 2026	Morgan Stanley	Terence Flynn	PT Cut	Overweight	$115→$114
Sep 8, 2026	BMO Capital	Evan Seigerman	Downgrade	Outperform→Market Perform	$128→$105
Aug 31, 2026	Canaccord Genuity	John Newman	PT Cut	Buy	$142→$136
Aug 5, 2026	Citigroup	Geoff Meacham	PT Cut	Buy	$130→$125
Aug 5, 2026	Evercore ISI Group	Cory Kasimov	PT Cut	Outperform	$135→$130
Jul 8, 2026	Morgan Stanley	Terence Flynn	PT Cut	Overweight	$126→$119
May 27, 2026	UBS	David Dai	Upgrade	Neutral→Buy	$117→$135
May 22, 2026	Bernstein	Jeffrey Walch	Initiate	Market Perform	$96
May 6, 2026	Canaccord Genuity	John Newman	PT Cut	Buy	$171→$158
May 6, 2026	Wells Fargo	Mohit Bansal	PT Cut	Overweight	$150→$140
Apr 27, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$130
Apr 10, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$125→$126
Mar 31, 2026	HC Wainwright & Co.	Robert Burns	PT Cut	Buy	$140→$130
Mar 11, 2026	Morgan Stanley	Terence Flynn	PT Cut	Overweight	$134→$125
Mar 11, 2026	Canaccord Genuity	John Newman	Maintained	Buy	$171
Mar 11, 2026	Citigroup	Geoff Meacham	PT Cut	Buy	$145→$130
Mar 11, 2026	TD Cowen	Yaron Werber	PT Cut	Hold	$116→$94
Mar 11, 2026	BMO Capital	Etzer Darout	PT Cut	Outperform	$143→$128
Mar 10, 2026	Jefferies	Akash Tewari	PT Cut	Buy	$151→$138

Analyst Ratings News

PRO
Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $132

Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $136 to $132.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $114

Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $115 to $114.

Benzinga Newsdesk

This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday

Analysts downgraded BioNTech, Gulfport Energy, Amgen and Best Buy; price targets fell for BioNTech and Gulfport.

Avi Kapoor

Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday

Analysts raised targets for NOW, HOOD, MSTR, ABNB and CLYM, while cutting APP and IONS; ratings largely remain positive.

Avi Kapoor

PRO
BMO Capital Downgrades BioNTech to Market Perform, Lowers Price Target to $105

BMO Capital analyst Evan Seigerman downgrades BioNTech (NASDAQ:BNTX) from Outperform to Market Perform and lowers the price target from $128 to $105.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $136

Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $142 to $136.

Benzinga Newsdesk